Introduction
============

Invasive lobular carcinoma (ILC) is defined as an invasive carcinoma comprising non-cohesive cells dispersed individually in a single-file linear pattern in a fibrous stroma and accounts for 5--15% of breast cancers.[@b1]--[@b3] A number of variants of ILC do not show the classical morphological pattern, but loss of cell-to-cell cohesion is a common feature.[@b3]

Histopathological grade is an important prognostic tool.[@b4]--[@b6] The Nottingham grading system classifies patients into groups with different prognoses.[@b7] However, in ILC the suitability of grading is uncertain.[@b8],[@b9] Glandular structures are absent, mitoses are infrequent and the nuclei uniform. Thus, most ILCs are grade 2 and the prognostic value of grading is unclear.

Breast cancer treatment guidelines are based on hormone receptor, human epidermal growth factor receptor 2 (HER2) and proliferation (Ki67) status, in addition to histopathological grade, tumour size and lymph node status.[@b10] Histopathological type is not always included as a parameter in treatment guidelines, although favourable types may influence the choice of treatment.

E-cadherin (E-cad) is a transmembrane protein involved in cell-to-cell adhesion, and its loss promotes invasion and metastasis.[@b11] Loss of E-cad is common in ILC,[@b11],[@b12] and supports the diagnosis of ILC.[@b13] Although it has been suggested that low levels of E-cad are associated with poorer prognosis,[@b14]--[@b16] its potential as a prognostic marker in ILC has not been clarified.

The aims of this study were to compare breast cancer-specific survival (BCSS) in ILC with invasive ductal carcinoma (IDC) in a cohort of breast cancer patients with a long follow-up, to assess the prognostic value of histopathological grading of ILC and to examine the potential of E-cad as a prognostic marker in ILC.

Material and methods
====================

Study population
----------------

Between 1956 and 1959, women from Nord Trøndelag County in Norway were invited by the Norwegian Cancer Registry to participate in a breast cancer survey. The population has been described previously.[@b17],[@b18] Briefly, 25 897 women, born between 1886 and 1928, were invited. From 1961 to 2008, 1393 women developed breast cancer. Cases occurring prior to 1961 were excluded. A total of 945 tissue samples were available at the Department of Pathology and Medical Genetics, St Olav\'s Hospital, Trondheim, Norway, and 867 were suitable for inclusion in tissue microarrays (TMA). After linkage with the Cause of Death Registry of Norway and the Norwegian Cancer Registry, survival data were generated. Only cases of IDC of no special type and ILC (727 cases) were included in the present study.

Specimen characteristics
------------------------

All cases were classified into histopathological type and grade and reclassified into molecular subtypes using surrogate markers for gene expression analyses (Figure[1](#fig01){ref-type="fig"}).[@b17] Histopathological typing and grading was performed independently on full-face sections by two experienced pathologists (O.A.H., A.M.B.).[@b3],[@b5],[@b19] Three 1-mm tissue cores from the periphery of each tumour were selected and assembled in TMAs. Immunohistochemical (IHC) staining was performed for oestrogen receptor (ER), progesterone receptor (PR), antigen Ki67 (Ki67), HER2, cytokeratin 5 (CK5) and epithelial growth factor receptor 1 (EGFR). *HER2* gene amplification status was estimated using chromogenic *in-situ* hybridization (CISH). For the present study, IHC staining was performed for E-cad.

![Classification algorithm for molecular subtyping.[@b17]](his0066-0409-f1){#fig01}

Assay methods
-------------

Assay methods for all markers except E-cad have been described in detail previously.[@b17] For the present study, IHC for detection of E-cad was performed according to the manufacturer\'s guidelines (Dako, Glostrup, Denmark). The sections were mounted on Superfrost+ glass slides, dried at 37°C overnight and stored at −20°C. Before staining, the slides were heated to 60°C for 2 h and pretreated in a PT Link pretreatment module for tissue specimens (Dako) with buffer (high pH target retrieval solution K8004) at 97°C for 20 min. Monoclonal mouse antibody (clone NCH-38), 55.2 mg/l dilution 1:100, was applied. For visualization, the Dako REAL™ EnVision™ detection system was used with peroxidase/diaminobenzidine (DAB)+, rabbit/mouse, code K5007.

Scoring and reporting
---------------------

The REMARK reporting recommendations for tumour marker studies were followed.[@b20] All IHC evaluations were performed independently by two researchers. ER and PR were positive if ≥1% of the tumour cells showed positive nuclear staining. For Ki67, ≥15% stained nuclei was classified as Ki67^high^ and \<15% as Ki67^low^. A staining index (SI) (intensity × proportion) was calculated for CK5 and EGFR; SI of 0--1 was considered to be negative and 2--9 was considered to be positive, as described previously. *HER2* gene amplification was defined as gene to chromosome ratio ≥2. In cases where CISH failed, +3 IHC staining for HER2 was recorded as positive.[@b17] In the present study, only moderate or strong continuous membrane staining for E-cad in \>50% of tumour cells were classified as positive. There were very few cases with aberrant staining (cytoplasmic staining or intermittent membranous staining), and these were classified as negative.

Statistical analyses
--------------------

Follow-up was from date of diagnosis until death or 31 December 2010. Kaplan--Meier methods were used to estimate BCSS for ILC grade 2 compared to IDC grades 1, 2 and 3, and for comparing survival of ILC and IDC grade 2, E-cad^+^ and E-cad^−^ tumours. Grade 2 ILC and IDC were compared for each of the following biomarker categories separately: ER+, Ki67^low^ and HER2^−^. Comparison was made between ILC and IDC grade 2 tumours with the favourable biomarker profile (ER^+^ and HER2^−^ and Ki67^low^). BCSS for luminal A and luminal B (HER2^−^) subtypes were compared for ILC and IDC separately. The log-rank test was used to compare survival curves, *P *\< 0.05 was considered statistically significant. Cox proportional hazards models were used to estimate relative risks of death from breast cancer adjusted for age (5-year intervals), stage at diagnosis (I, II, III, IV, unknown) and time-period of diagnosis. Hazard ratios (HR) for ILC compared to IDC were calculated with 95% confidence intervals (CI). The numbers of cases of ILC grades 1 and 3 were too low for reliable analyses of grade and BCSS in ILC. The number of cases with an unfavourable biomarker profile (ER^−^, HER2^+^ and Ki67^high^) was too small for separate analysis (*n *=* *39). Statistical analyses were performed using Stata version 12.1 (Stata Corp., College Station, TX, USA).

Ethics
------

Approval was granted by the Regional Committee for Medical and Health Sciences Research Ethics, including dispensation from the requirement of patient consent (REK, Midt-Norge, ref. no. 836/2009).

Results
=======

Description of the population
-----------------------------

Of the 727 cases, 16% were ILC and 84% were IDC (Table[1](#tbl1){ref-type="table"}). During follow-up, 297 (40.9%) died from breast cancer and 304 (41.8%) died of other causes. At the end of the period, 126 (17.3%) were still alive. Mean age at diagnosis was 71.3 years for IDC and 73.3 years for ILC. Table[2](#tbl2){ref-type="table"} shows the treatments given.

###### 

Summary of patient and tumour characteristics

  Patient and tumour characteristics                Ductal        Lobular      Total
  ------------------------------------------------- ------------- ------------ -------------
  Number (%)                                        611 (84.0)    116 (16.0)   727 (100.0)
  Number of breast cancer deaths (%)                246 (40.3)    51 (44.0)    297 (40.9)
  Mean age at diagnosis (SD)                        71.3 (10.7)   73.3 (9.1)   71.7 (10.5)
  Median years of follow-up after diagnosis (IQR)   7.2 (10.6)    4.8 (7.9)    6.8 (10.4)
  Tumour grade (%)                                                             
   1                                                61 (10.0)     9 (7.8)      70 (9.6)
   2                                                317 (51.9)    99 (85.3)    416 (57.2)
   3                                                233 (38.1)    8 (6.9)      241 (33.2)
  Tumour size (%)                                                              
   ≤2 cm                                            182 (29.8)    20 (17.2)    202 (27.8)
   \>2 cm, ≤5 cm                                    221 (36.2)    43 (37.1)    264 (36.3)
   \>5 cm                                           46 (7.5)      19 (16.4)    65 (8.9)
   Uncertain                                        162 (26.1)    34 (29.3)    196 (27.0)
  Lymph node status                                                            
   No metastasis                                    234 (38.3)    45 (38.8)    279 (38.4)
   Metastasis detected                              236 (38.6)    38 (32.8)    274 (37.7)
   Not examined for metastasis                      141 (23.1)    33 (28.4)    174 (23.9)
  Stage at diagnosis                                                           
   Stage I                                          294 (48.1)    52 (44.8)    346 (47.6)
   Stage II                                         246 (40.3)    49 (42.2)    295 (40.6)
   Stage III                                        37 (6.1)      11 (9.5)     48 (6.6)
   Stage IV                                         29 (4.8)      4 (3.5)      33 (4.5)
   Stage uncertain                                  5 (0.8)       0            5 (0.7)
  Molecular subtypes (%)                                                       
   Luminal A                                        290 (47.5)    63 (54.3)    353 (48.6)
   Luminal B (HER2^−^)                              170 (27.8)    33 (28.5)    203 (27.9)
   Luminal B (HER2^+^)                              54 (8.8)      6 (5.2)      60 (8.3)
   HER2 type                                        49 (8.0)      1 (0.9)      50 (6.9)
   Five negative phenotype                          13 (2.1)      11 (9.5)     24 (3.3)
   Basal phenotype                                  35 (5.7)      2 (1.7)      37 (5.1)

SD, standard deviation; IQR, interquartile range; HER2, human epidermal growth factor receptor 2.

###### 

Summary of breast cancer therapies for all cases

                                                     Invasive ductal carcinoma *n *=* *611 (%)       Invasive lobular carcinoma *n *=* *116 (%)     Total *n *=* *727 (%)
  -------------------------------------------------- ----------------------------------------------- ---------------------------------------------- -----------------------------------------------
  Mastectomy                                         524 (85.8)                                      94 (81.0)                                      618 (85.0)
  Breast conserving therapy                          61 (10.0)                                       12 (10.4)                                      73 (10.0)
  Only biopsy, no surgical treatment                 26 (4.3)                                        10 (8.6)                                       36 (5.0)
  Axillary surgery (clearance or sentinel node)      461 (75.5)                                      81 (69.9)                                      542 (74.6)
  Hormone therapy[\*](#tf2-1){ref-type="table-fn"}   134 (26.2[\*\*](#tf2-2){ref-type="table-fn"})   31 (30.4[\*\*](#tf2-2){ref-type="table-fn"})   165 (26.9[\*\*)](#tf2-2){ref-type="table-fn"}
  Trastuzumab                                        0                                               0                                              0
  Chemotherapy                                       Unknown                                         Unknown                                        Unknown
  Radiation                                          Unknown                                         Unknown                                        Unknown

Estimated according to guidelines at diagnosis;

\% of the hormone receptor-positive cases.

Tumour characteristics
----------------------

Histopathological grade, tumour size, lymph node status, stage and molecular subtypes are given in Table[1](#tbl1){ref-type="table"}. Table[3](#tbl3){ref-type="table"} shows the results of IHC and CISH. The proportion of histopathological grade 2 tumours was higher in ILC (85.3%) compared to IDC (51.9%). In ILC 87.9% were ER^+^ and 6.0% were HER2^+^, compared to 83.6% ER^+^ and 16.9% HER2^+^ in IDC. A higher proportion of ILC (16.4%) than IDC (7.5%) were \>5 cm. However, the proportions of tumours between 2 and 5 cm were similar (42.2 versus 45.5%).

###### 

Results of immunohistochemical and *in-situ* hybridization markers

                              Ductal (*n *=* *611)   Lobular (*n *=* *116)   Total (*n *=* *727)
  --------------------------- ---------------------- ----------------------- ---------------------
  ER^+^                       511 (83.6)             102 (87.9)              613 (84.3)
  ER^−^                       98 (16.0)              14 (12.1)               112 (15.4)
  Not possible to interpret   2 (0.3)                0                       2 (0.3)
  PR^+^                       364 (59.6)             58 (50.0)               422 (58.1)
  PR^−^                       246 (40.3)             58 (50.0)               304 (41.8)
  Not possible to interpret   1 (0.2)                0                       1 (0.1)
  HER2^+^                     103 (16.9)             7 (6.0)                 110 (15.1)
  HER2^−^                     508 (83.1)             109 (94.0)              617 (84.9)
  Ki67^high^                  280 (45.8)             39 (33.6)               319 (43.9)
  Ki67^low^                   330 (54.0)             77 (66.4)               407 (56.0)
  Not possible to interpret   1 (0.2)                0                       1 (0.1)
  CK5^+^                      120 (19.6)             4 (3.5)                 124 (17.1)
  CK5^−^                      491 (80.4)             112 (96.6)              603 (82.9)
  EGFR^+^                     41 (6.7)               3 (2.6)                 44 (6.1)
  EGFR^−^                     570 (93.3)             113 (97.4)              683 (93.9)
  E-cad^+^                    523 (85.6)             27 (23.3)               550 (75.7)
  E-cad^−^                    69 (11.3)              86 (74.1)               155 (21.3)
  Not possible to interpret   19 (3.1)               3 (2.6)                 22 (3.0)

EGFR, epithelial growth factor receptor; ER, oestrogen receptor; PR, progesterone receptor.

Grade, type and prognosis
-------------------------

Figure[2](#fig02){ref-type="fig"} shows BCSS for ILC grade 2 compared to IDC grades 1, 2 and 3. ILC grade 2 had poorer BCSS compared to IDC grade 2 (*P *=* *0.01, log-rank test).There was no significant difference in BCSS between ILC grade 2 and IDC grade 3 (*P *=* *0.48, log-rank test). Table[4](#tbl4){ref-type="table"} shows the risk of death from breast cancer according to type. ILC grade 2 was compared to IDC grades 1, 2 and 3 separately. HRs were similar for ILC grade 2 and IDC grade 3, whereas IDC grade 2 had a significantly better survival than ILC grade 2 (HR: 0.66, 95% CI: 0.46--0.94). Adjustment for age, stage and time of diagnosis did not influence the results.

###### 

Risk of death from breast cancer. Invasive lobular carcinoma grade 2 compared to invasive ductal carcinoma grades 1, 2 and 3

  Tumour characteristics   Number of cases   Deaths from breast cancer   HR 95%CI   HR 95%CI     HR 95%CI   HR 95%CI                                
  ------------------------ ----------------- --------------------------- ---------- ------------ ---------- ------------ ------ ------------ ------ ------------
  Lobular grade 2          99                42                          1.00                    1.00                    1.00                1.00   
  Ductal grade 1           61                17                          0.43       0.24--0.75   0.47       0.27--0.84   0.49   0.28--0.87   0.40   0.23--0.71
  Ductal grade 2           317               114                         0.66       0.46--0.94   0.67       0.47--0.95   0.59   0.41--0.85   0.66   0.46--0.94
  Ductal grade 3           233               115                         1.10       0.77--1.56   1.13       0.79--1.61   1.10   0.77--1.57   1.03   0.72--1.47
                           710               297                                                                                                    

HR, hazard ratio; CI, confidence interval.

![Breast cancer specific survival for invasive lobular carcinoma grade 2 compared to ductal carcinoma grades 1, 2 and 3. *P*-value from log-rank test of differences in breast cancer specific survival (BCSS) was 0.01.](his0066-0409-f2){#fig02}

Prognostic value of type in ER^+^, HER2^−^ and KI67^LOW^ tumours
----------------------------------------------------------------

Table[5](#tbl5){ref-type="table"} shows risk of death from breast cancer according to type among patients with grade 2 tumours and clinically favourable biomarker profiles. For each marker status (ER^+^, HER2^−^, Ki67^low^), respectively, there was a significantly higher risk of death from ILC compared to IDC. Similarly, risk of death from breast cancer for patients with grade 2 tumours expressing a complete favourable biomarker profile (ER^+^, HER2^−^ and Ki67^low^) was higher for ILC than for IDC (HR: 2.16, 95% CI: 1.34--3.49). Analysis of all grades did not alter the results (data not shown).

###### 

Risk of death from invasive lobular grade 2 compared to invasive ductal carcinoma grade 2

  Tumour characteristics         Number of cases   Deaths from breast cancer   HR 95% CI   HR 95% CI    HR 95% CI   HR 95% CI                                          
  ------------------------------ ----------------- --------------------------- ----------- ------------ ----------- ------------ ----------------- ------------ ------ ------------
  ER^+^                                                                                                                                                                
   Ductal                        297               100                         1.00                     1.00                     1.00                           1.00   
   Lobular                       88                37                          1.71        1.17--2.50   1.68        1.14--2.47   1.97              1.33--2.91   1.82   1.24--2.68
                                 385               137                                                                                                                 
  Ki67^low^                                                                                                                                                            
   Ductal                        224               71                          1.00                     1.00                     1.00                           1.00   
   Lobular                       70                30                          2.01        1.31--3.01   1.95        1.26--3.03   2.20              1.42--3.43   2.03   1.31--3.14
                                 294               101                                                                                                                 
  HER2^−^                                                                                                                                                              
   Ductal                        287               97                          1.00                     1.00                     1.00                           1.00   
   Lobular                       93                39                          1.76        1.21--2.56   1.74        1.19--2.55   1.98 1.30--2.90   1.22--2.60   1.78   1.22--2.60
                                 380               136                                                                                                                 
  ER^+^, Ki67^low^ and HER2^−^                                                                                                                                         
   Ductal                        201               61                          1.00                     1.00                     1.00                           1.00   
   Lobular                       56                24                          2.16        1.34--3.49   2.04        1.25--3.34   2.45              1.50--4.01   2.31   1.42--3.76
                                 257               85                                                                                                                  

HR, hazard ratio; CI, confidence interval; HER2, human epidermal growth factor receptor 2.

Prognostic value of molecular subtypes
--------------------------------------

The proportions of HER2^+^ and/or ER^−^ ILC were low compared to IDC, as reflected in the distribution of molecular subtypes (Table[1](#tbl1){ref-type="table"}). Among 353 luminal A cases, 290 (82.2%) were ductal and 63 (17.8%) were lobular. Figure[3](#fig03){ref-type="fig"} shows that luminal A ILC had a poorer prognosis than luminal A IDC (*P *=* *0.02, log-rank test). Luminal B (HER2^−^) IDC had a slightly better prognosis than luminal A and luminal B (HER2^−^) ILC (*P *=* *0.39, log-rank test). Table[6](#tbl6){ref-type="table"} shows that risk of death from grade 2 breast cancer was higher for luminal A ILC, luminal B (HER2^−^) ILC and luminal B (HER2^−^) IDC compared to luminal A IDC. The difference between luminal A IDC and ILC was statistically significant. The numbers in the other subtypes were too low for analysis.

###### 

Risk of death from invasive lobular carcinoma grade 2 and invasive ductal carcinoma grade 2 according to luminal A and luminal B (HER2^−^) subtypes

                                Number of cases   Deaths from breast cancer   HR 95% CI   HR 95% CI    HR 95% CI   HR 95% CI                               
  ----------------------------- ----------------- --------------------------- ----------- ------------ ----------- ------------ ------ ------------ ------ ------------
  Ductal luminal A              203               62                          1.00                     1.00                     1.00                1.00   
  Ductal luminal B (HER2^−^)    74                29                          1.48        0.95--2.31   1.55        0.99--2.42   1.70   1.09--2.67   1.36   0.87--2.12
  Lobular luminal A             56                24                          2.11        1.31--3.39   2.08        1.28--3.38   2.53   1.55--4.12   2.21   1.36--3.57
  Lobular luminal B (HER2^−^)   26                10                          1.78        0.91--3.48   1.81        0.92--3.57   2.10   1.07--4.14   1.74   0.88--3.41
                                359               125                                                                                                      

HR, hazard ratio; CI, confidence interval; HER2, human epidermal growth factor receptor 2.

![Breast cancer specific survival for invasive lobular and ductal carcinoma grade 2 according to luminal A and luminal B \[human epidermal growth factor receptor 2 (HER2)\] subtypes. *P*-value from log-rank test of differences in breast cancer specific survival (BCSS) was 0.02.](his0066-0409-f3){#fig03}

Prognostic value of E-cadherin
------------------------------

Table[3](#tbl3){ref-type="table"} shows that 23.3% of ILC were E-cad^+^. Figure[4](#fig04){ref-type="fig"} shows BCSS for grade 2 E-cad^+^ and E-cad^−^ ILC and IDC. E-cad^−^ ILC had poorer prognosis than E-cad^+^ ILC (*P *=* *0.005, log-rank test). Figure[5](#fig05){ref-type="fig"} shows examples of E-cad IHC staining. Table[7](#tbl7){ref-type="table"} shows that risk of death from breast cancer for ILC E-cad^−^ was nearly twofold (HR: 1.96, 95% CI: 1.32--2.89) compared to IDC E-cad^+^. There was no clear difference in prognosis between IDC E-cad^+^, IDC E-cad^−^ and ILC E-cad^+^. Adjustment for age, stage and time-period did not influence the results.

###### 

Risk of death from invasive lobular carcinoma grade 2 and invasive ductal carcinoma grade 2 according to E-cadherin status

                      Number of cases   Deaths from breast cancer   HR 95% CI   HR 95% CI    HR 95% CI   HR 95% CI                               
  ------------------- ----------------- --------------------------- ----------- ------------ ----------- ------------ ------ ------------ ------ ------------
  Ductal, E-cad^+^    260               94                          1.00                     1.00                     1.00                1.00   
  Ductal, E-cad^−^    46                16                          1.03        0.61--1.75   1.00        0.59--1.71   1.17   0.68--2.00   1.03   0.60--1.76
  Lobular, E-cad^+^   24                7                           0.84        0.39--1.81   0.86        0.40--1.88   0.87   0.40--1.89   0.83   0.38--1.79
  Lobular, E-cad^−^   74                35                          1.96        1.32--2.89   1.88        1.27--2.80   2.30   1.54--3.44   2.03   1.36--3.01
                      404               152                                                                                                      

HR, hazard ratio; CI, confidence interval.

![Breast cancer specific survival for for invasive lobular and ductal carcinoma grade 2 according to E-cadherin status. *P*-value from log-rank test of differences in breast cancer specific survival (BCSS) was 0.005.](his0066-0409-f4){#fig04}

![Invasive lobular carcinoma (ILC): A,ILC stained wih Haematoxylin--erythrosin--saffron (HES). B, Same case as A. Positive membrane staining for E-cadherin. C, ILC HES. D, Same case as C. No membrane staining for E-cadherin.](his0066-0409-f5){#fig05}

Discussion
==========

The main finding in this study of a cohort of breast cancer patients with long-term follow-up was a significantly poorer prognosis for grade 2 ILC compared to grade 2 IDC. The prognosis for grade 2 ILC was comparable to that of grade 3 IDC. A similar pattern was observed when the analyses were restricted to tumours with positive prognostic marker profiles (ER^+^, HER2^−^ and Ki67^low^). Furthermore, E-cad expression appeared to be a favourable prognostic marker in ILC.

In the Nottingham grading system gland formation, nuclear atypia/pleomorphism and mitosis counts are considered.[@b5] However, because the morphological features of ILC differ from IDC, grade may have a different prognostic significance.[@b8],[@b21] This is an important discussion, because histopathological grade is one of several factors determining adjuvant therapy, whereas type is disregarded.

In agreement with others,[@b1],[@b21],[@b22] there were few ILCs of grade 1 (7.8%) and grade 3 (6.9%) in this study, and the low numbers preclude survival analyses. Histopathological grading has been shown to be of independent prognostic value in ILC.[@b23] However, the implications of grading in ILC may differ from IDC and its value as a prognostic tool must be considered in this light, particularly when determining treatment strategies.

ER, HER2 and Ki67 are important prognostic and/or predictive markers. In this study, the proportion of ILCs with a favourable marker profile was higher compared to IDC, implying a better prognosis for ILC. However, even when restricting analyses to cases with favourable marker profiles, a significantly poorer prognosis was found in ILC compared to IDC. HER2^+^ cases in ILC were few (Table[2](#tbl2){ref-type="table"}), thus limiting its utility as a prognostic marker in ILC. Better prognostic markers for ILC are required.

In this study, E-cad^+^ grade 2 ILC was prognostically comparable to grade 2 IDC (both E-cad^+^ and E-cad^−^). E-cad- ILC had a poorer prognosis. The identification of patients with ILC of expected poor prognosis may have implications when determining adjuvant therapy. If the prognostic utility of E-cad for ILC is confirmed in future studies and robust guidelines for interpretation of E-cad IHC are developed,[@b14],[@b15] this could extend the use of a well-known marker for the benefit of a substantial proportion of breast cancer patients.

The loss of E-cad expression is shown to promote invasion and metastasis of epithelial cancers, including breast cancer.[@b24] E-cad may be involved in other cellular processes of importance as a tumour suppressor gene.[@b25] Cell-to-cell adhesion involves cytoplasmic catenins and the actin cytoskeleton in addition to E-cad, and these mechanisms are complex.[@b26] Loss of tumour suppressor function and impaired cell-to-cell adhesion, both of which are dependent in part on E-cad, underline the importance of this molecule in breast cancer.

The proportion of E-cad^+^ ILC reported varies from 0 to 20%.[@b27]--[@b29] In this study, where histopathological typing was based on morphology only, 23.3% were E-cad^+^. No cases were revised according to histopathological type in light of E-cad status. Mixed lobular and ductal carcinomas are not infrequent.[@b3] In this study, mixed tumours were classified as ductal.[@b27],[@b30],[@b31]

Molecular subtyping is based mainly on studies of IDC.[@b32] IDC is the most common histopathological type, although type is rarely mentioned.[@b33]--[@b35] For other types, the prognostic value of molecular subtyping remains uncertain. In this study, there were too few ILCs in the non-luminal and HER2 subtypes for reliable results. However, the differences in BCSS in the HER2^−^ luminal subtypes between ILC and IDC are comparable to the results of the biomarker analyses. Considered together, the results confirm that histopathological type has an independent impact in the prognostication of ILC.

The main strength of this study is the historical nature of the patient cohort enabling complete long-term follow-up. The vast majority of women in this study developed breast cancer in an era prior to the use of hormonal contraception, menopausal hormonal therapy (MHT) and mammography screening, and did not qualify for new therapies as they were introduced, thus enabling insight into the near-natural course of this disease. A drawback is the relative high age of the women, and should be considered when interpreting the results. Others have shown better,[@b36] similar[@b2],[@b37] or poorer[@b38],[@b39] prognosis for ILC compared to IDC. Differences in patient populations, follow-up and adjuvant therapy may explain these inconsistencies. Some studies have shown an increased risk of ILC when using MHT.[@b40]--[@b42] It is unclear whether or not there are differences in prognosis between MHT-associated ILC and ILC in non-users.[@b43] The majority of cancers in the present study were diagnosed in a time-period or at an age when MHT was rarely used.

In this study, 99 of 116 ILCs were histopathological grade 2. The numbers of grades 1 and 3 were low, and this can be attributed to the morphological features of ILC. This impairs grading as a prognostic tool in ILC. Similarly, the prognostic value of HER2 in ILC may be limited due to the low number of ILCs expressing HER2. However, grade 2 ILC had a consistently poorer prognosis when compared to grade 2 IDC, and the differences were also apparent when the analyses included only tumours with presumed favourable biomarkers. Due to the low number of lobular tumours in our study, we did not have sufficient statistical power to investigate the prognostic value of an unfavourable biomarker profile within lobular cancers. The present study supports the claim that lobular lesions are a distinct family of neoplastic lesions in the breast.[@b12] The role of E-cad in ILC may not only be in the determination of histopathological type; it may also be more useful than grade in prognostication and in the determination of treatment.
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